Asunto(s)
Aminoquinolinas/inmunología , Antimaláricos/inmunología , Deficiencia de Glucosafosfato Deshidrogenasa/inmunología , Tamizaje Masivo/métodos , Vigilancia de la Población/métodos , Contraindicaciones de los Medicamentos , Femenino , Deficiencia de Glucosafosfato Deshidrogenasa/epidemiología , Deficiencia de Glucosafosfato Deshidrogenasa/parasitología , Humanos , Malaria Vivax/prevención & control , Masculino , Personal Militar/estadística & datos numéricos , Plasmodium vivax/inmunología , Prevalencia , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Psoriasis, a common inflammatory skin disorder characterized by scaly erythema and plaques, is induced by dysregulation of dendritic cell- and T cell-mediated immune reaction. Receptor-interacting protein kinase 1 (RIPK1) regulates inflammatory signaling in response to stimuli such as TNF-α, TRAIL, and TLRs, resulting in apoptosis, necroptosis and NF-κB activation. However, the physiological relevance in human epidermis remains elusive. OBJECTIVE: In this study, we examined whether RIPK1 is involved in the pathogenesis of psoriasis vulgaris. METHODS: Skin samples of eight patients with psoriasis vulgaris were investigated by western blotting and immunohistochemistry. The functions of RIPK1 in keratinocytes were examined by RT-PCR and ELISA in vitro. TRAIL-neutralization-experiment was employed in an imiquimod-induced murine psoriasis model. RESULTS: In lesional psoriatic epidermis, RIPK1-expression was decreased compared with that in normal epidermis. Cytokines involved in the pathomechanism of psoriasis, such as IL-1ß, IL-17A, IL-22 and TRAIL, reduced RIPK1-expression in normal human epidermal keratinocytes (HEK) in vitro. In addition, RIPK1-knockdown enhanced TRAIL-mediated expression of psoriasis-relating cytokines, such as IL-1ß, IL-6, IL-8, TNF-α, in HEK. Numerous TRAIL-positive cells were detected in the dermis of lesional psoriatic skin, and TRAIL receptors were expressed in psoriatic epidermis and HEK in conventional cultures. Moreover, TRAIL-neutralization in an imiquimod-induced murine psoriasis model remarkably improved skin phenotypes, such as ear thickness, and TNF-α expression in lesional skin. CONCLUSIONS: These results lead us to conclude that RIPK1-downregulation in keratinocytes increases their susceptibility to TRAIL stimulation, and plays a role in the pathogenesis of psoriasis vulgaris.
Asunto(s)
Citocinas/metabolismo , Queratinocitos/patología , Psoriasis/patología , Proteína Serina-Treonina Quinasas de Interacción con Receptores/metabolismo , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Aminoquinolinas/inmunología , Animales , Células Cultivadas , Modelos Animales de Enfermedad , Regulación hacia Abajo , Células Epidérmicas , Epidermis/inmunología , Epidermis/patología , Femenino , Técnicas de Silenciamiento del Gen , Humanos , Imiquimod , Ratones , Ratones Endogámicos C57BL , Cultivo Primario de Células , Psoriasis/inmunología , ARN Interferente Pequeño/metabolismo , Proteína Serina-Treonina Quinasas de Interacción con Receptores/genética , Transducción de Señal/inmunología , Ligando Inductor de Apoptosis Relacionado con TNF/antagonistas & inhibidoresRESUMEN
BACKGROUND: Langerhans cells (LCs) are dendritic cells that reside in the epidermis and local inflammation results in an increased differentiation of monocyte-derived LCs. Only few studies have investigated on the role of LCs in psoriasis-like dermatitis model, but the results are variable and the exact role of LCs in psoriasis model remains to be elucidated. OBJECTIVE: To explore the functional role of resident (rLCs) and monocyte-derived LCs (mLCs) in imiquimod (IMQ)-induced psoriasis-like inflammation using human Langerin-diphtheria toxin subunit A (huLang-DTA) mice. METHODS: 5% IMQ cream was topically applied on the skins. Clinical and histopathological features were evaluated. Psoriasis-related gene expression was analyzed by quantitative polymerase chain reaction. The production of psoriasis-related cytokines including IL-17A and IL-22 by T cells were assessed by flow cytometry from the lesional skins. RESULTS: huLang-DTA mice showed a common depletion of both rLCs and mLCs in the IMQ-treated skins. huLang-DTA mice had a reduced IMQ-induced psoriasis-like inflammation featuring erythema, scale, and thickness compared with wild-type mice. Psoriatic lesions from huLang-DTA mice had a decreased level of Il23a and accordingly demonstrated an attenuated cytokine production of IL-17A and IL-22 from γδlow T cells. mLCs revealed a significantly greater level of IL-23 expression compared to rLCs in response to topical IMQ treatment. CONCLUSION: Although both rLCs and mLCs are involved in the development of IMQ-induced psoriasis-like dermatitis, inflammation-induced mLCs present a superior capacity for producing IL-23 in this murine experimental model of psoriasis.
Asunto(s)
Citocinas/metabolismo , Células de Langerhans/inmunología , Psoriasis/inmunología , Aminoquinolinas/inmunología , Animales , Antígenos CD/genética , Citocinas/inmunología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Modelos Animales de Enfermedad , Células Epidérmicas , Epidermis/inmunología , Epidermis/metabolismo , Epidermis/patología , Femenino , Perfilación de la Expresión Génica , Humanos , Imiquimod , Células de Langerhans/metabolismo , Lectinas Tipo C/genética , Masculino , Lectinas de Unión a Manosa/genética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Monocitos/fisiología , Psoriasis/patologíaRESUMEN
BACKGROUNDS: IFN regulatory factor (IRF)-2 is one of the potential susceptibility genes for psoriasis, but how this gene influences psoriasis pathogenesis is unclear. Topical application of imiquimod (IMQ), a TLR7 ligand, induces psoriasis-like skin lesions in mice. OBJECTIVE: The aim of this study was to investigate whether IRF-2 gene status would influence severity of skin disease in IMQ-treated mice. METHODS: Imiquimod-induced psoriasis-like skin inflammation was assessed by clinical findings, histology, and cytokine expression. The effects of imiquimod or IFN on peritoneal macrophages were analyzed in vitro. RESULTS: IMQ-induced skin inflammation assessed by clinical findings and histology was more severe in IRF-2+/- mice than in wild-type mice. In inflamed skin, mRNA expression levels of tumor necrosis factor (TNF)-α, IL-12/23p40, IL-17A, and IL-22 were significantly elevated in IRF-2+/- mice compared to wild-type mice. Stimulation of peritoneal macrophages by IMQ significantly increased mRNA levels of TNF-α, IL-12/23p40, IL-23p19, IL-12p35, and IL-36. Interestingly, macrophages from IRF-2+/- mice expressed higher levels of TNF-α, IL-12/23p40, and IL-36 compared to those from wild-type mice 24â¯h after stimulation, while they expressed similar levels of IL-12p35 and IL-23p19. Moreover, elevated mRNA expression of inducible nitric oxide synthase was observed only in IMQ-stimulated macrophages derived from IRF-2+/- mice, which correlated with angiogenesis in IMQ-treated ears of IRF-2+/- mice. CONCLUSIONS: These results suggest that IRF-2 haploinsufficiency creates heightened biologic responses to IFN-α that phenotypically lead to enhanced angiogenesis and psoriasis-like inflammation within skin.
Asunto(s)
Factor 2 Regulador del Interferón/genética , Interferón-alfa/metabolismo , Neovascularización Patológica/genética , Psoriasis/genética , Aminoquinolinas/inmunología , Aminoquinolinas/farmacología , Animales , Modelos Animales de Enfermedad , Haploinsuficiencia , Humanos , Imiquimod , Factor 2 Regulador del Interferón/metabolismo , Interferón-alfa/genética , Queratinocitos/metabolismo , Macrófagos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Óxido Nítrico Sintasa de Tipo II/metabolismo , Psoriasis/inmunología , Psoriasis/patología , ARN Mensajero/metabolismo , Índice de Severidad de la Enfermedad , Piel/irrigación sanguínea , Piel/citología , Piel/patologíaRESUMEN
Keratin-17 (K17) is a cytoskeletal protein produced by keratinocytes (KCs), which is overexpressed in psoriasis and may play a pivotal role in its pathogenesis. Narrow-band ultraviolet B (NB-UVB) irradiation is used as a general treatment for psoriasis, although its impact on K17 expression has yet to be determined. In this study, we aimed to investigate the effect of NB-UVB irradiation on K17 expression and its signaling pathways. After exposure to NB-UVB irradiation, immortalized human keratinocytes (HaCaT cells) were analyzed by flow cytometry, CCK-8 assays and transmission electron microscopy to examine proliferation. Meanwhile, K17 expression in primary human epithelial keratinocytes was detected by quantitative real-time polymerase chain reaction (qRT-PCR), western blot analysis and immunofluorescence. HaCaT cells pre-incubated with PD-98059 and piceatannol were subjected to western blot analysis to examine ERK1/2 and STAT3 phosphorylation. The ears of mice treated with imiquimod (IMQ) and irradiated by NB-UVB were taken to examine K17 expression by qRT-PCR, western blot analysis, and immunofluorescence. Our results showed that 400 mJ/cm2 of NB-UVB irradiation was the maximum tolerable dose for HaCaT cells and could cause inhibited HaCaT cell proliferation and moderate increase of the early apoptosis. Furthermore, NB-UVB irradiation could downregulate K17 expression by inhibiting the ERK1/2 and STAT3 signaling pathways. In experiments conducted in vivo, NB-UVB irradiation with doses of MED or higher could eliminate the IMQ-induced psoriasis-like dermatitis and inhibit K17 expression. These results indicated that NB-UVB irradiation may eliminate chronic psoriatic plaques by suppressing K17 expression via the ERK1/2 and STAT3 signaling pathways.
Asunto(s)
Queratina-17/metabolismo , Queratinocitos/efectos de la radiación , Queratinas/metabolismo , Psoriasis/radioterapia , Transducción de Señal/efectos de la radiación , Terapia Ultravioleta/métodos , Aminoquinolinas/inmunología , Animales , Apoptosis/efectos de la radiación , Biomarcadores/metabolismo , Línea Celular , Proliferación Celular/efectos de la radiación , Modelos Animales de Enfermedad , Regulación hacia Abajo , Femenino , Voluntarios Sanos , Humanos , Imiquimod , Queratinocitos/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica de Transmisión , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Cultivo Primario de Células , Psoriasis/inducido químicamente , Psoriasis/inmunología , Psoriasis/patología , Dosis de Radiación , Factor de Transcripción STAT3/metabolismo , Piel/citología , Piel/patología , Piel/efectos de la radiación , Resultado del TratamientoRESUMEN
Monocytes comprise several subsets with distinct phenotypes and functional capacities. Based on CD163 expression, two major monocyte subsets can be discriminated in the porcine bone marrow. The CD163+ cells expressed higher levels of SLA-DR, Siglec-1, CD11R1 and CD16 when compared to CD163- monocytes, whereas no remarkable differences were observed in the expression of other markers analyzed. Gene expression analysis showed differential expression of several chemokine receptor and TLR genes. Both subsets phagocytosed microspheres with similar efficiency. However, CD163- cells tended to produce higher levels of ROS in response to PMA, whereas CD163+ cells were more efficient in endocytosing and processing antigens (DQ-OVA). CD163- monocytes produced higher levels of TNF-α and IL-10 than CD163+ cells when stimulated with LPS or Imiquimod. Both subsets produced similar amounts of IL-8 in response to LPS; however, CD163+ cells produced more IL-8 after Imiquimod stimulation. Whether these subsets represent different developmental stages, and how are they related remain to be investigated.
Asunto(s)
Células de la Médula Ósea/inmunología , Monocitos/inmunología , Porcinos/inmunología , Aminoquinolinas/inmunología , Animales , Presentación de Antígeno , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Células Cultivadas , Endocitosis , Antígenos de Histocompatibilidad/metabolismo , Imiquimod , Interleucina-10/metabolismo , Interleucina-8/metabolismo , Lipopolisacáridos/inmunología , Estrés Oxidativo , Fenotipo , Receptores de Superficie Celular/metabolismo , Receptores de Quimiocina/genética , Receptores de Quimiocina/metabolismo , Receptores Toll-Like/genética , Receptores Toll-Like/metabolismo , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Endothelial cell (EC) dysfunction has been associated with inflammatory and autoimmune diseases; however, the factors contributing to this dysfunction have not been fully explored. Because activation of TLRs has been implicated in autoimmune diseases, the goal of this study was to determine the effects of TLR ligands on EC function. Human dermal microvascular ECs (HDMECs) treated with TLR3 [Poly(I:C)], TLR4 (LPS), and TLR7 (imiquimod) agonists showed decreased proliferation and a reduced total number of branching tubules in three-dimensional human dermal organoid ex vivo culture. In contrast, the TLR9 ligand class C, ODN2395, increased angiogenesis. The antiproliferative effects of TLR3, TLR4, and TLR7 ligands correlated with significant downregulation of a key regulator of vascular homeostasis, Fli1, whereas TLR9 increased Fli1 levels. Furthermore, Poly(I:C) and LPS induced endothelial to mesenchymal transition that was reversed by the pretreatment with TGF-ß neutralizing Ab or re-expression of Fli1. We showed that Fli1 was required for the HDMEC proliferation by transcriptionally repressing FOXO3A. In contrast to TLR9, which suppressed activation of the FOXO3A pathway, TLR3, TLR4, and TLR7 ligands activated FOXO3A as indicated by decreased phosphorylation and increased nuclear accumulation. The inverse correlation between Fli1 and FOXO3A was also observed in the vasculature of scleroderma patients. This work revealed opposing effects of TLR9 and TLR3, TLR4, and TLR7 on the key angiogenic pathways, Fli1 and FOXO3A. Our results provide a mechanistic insight into the regulation of angiogenesis by TLRs and confirm a central role of Fli1 in regulating vascular homeostasis.
Asunto(s)
Dermis/patología , Endotelio Vascular/inmunología , Proteína Forkhead Box O3/metabolismo , Microvasos , Proteína Proto-Oncogénica c-fli-1/metabolismo , Esclerodermia Limitada/inmunología , Adulto , Aminoquinolinas/inmunología , Línea Celular , Femenino , Humanos , Imiquimod , Lipopolisacáridos/inmunología , Masculino , Persona de Mediana Edad , Oligodesoxirribonucleótidos/inmunología , Poli I-C/inmunología , Proteína Proto-Oncogénica c-fli-1/genética , ARN Interferente Pequeño/genética , Transducción de Señal , Receptores Toll-Like/metabolismo , Factor de Crecimiento Transformador beta/inmunología , Factor de Crecimiento Transformador beta/metabolismoRESUMEN
Caspase recruitment domain family member 14 (CARD14) was recently identified as a psoriasis-susceptibility gene, but its immunological role in the pathogenesis of psoriasis in vivo remains unclear. In this study, we examined the role of CARD14 in murine experimental models of psoriasis induced by either imiquimod (IMQ) cream or recombinant IL-23 injection. In all models tested, the psoriasiform skin inflammation was abrogated in Card14-/- mice. Comparison of the early gene signature of the skin between IMQ-cream-treated Card14-/- mice and Tlr7-/-Tlr9-/- mice revealed not only their similarity, but also distinct gene sets targeted by IL-23. Cell type-specific analysis of these mice identified skin Langerinhigh Langerhans cells as a potent producer of IL-23, which was dependent on both TLR7 and TLR9 but independent of CARD14, suggesting that CARD14 is acting downstream of IL-23, not TLR7 or TLR9. Instead, a bone marrow chimera study suggested that CARD14 in radio-sensitive hematopoietic cells was required for IMQ-induced psoriasiform skin inflammation, controlling the number of Vγ4+ T cells producing IL-17 or IL-22 infiltrating through the dermis to the inflamed epidermis. These data indicate that CARD14 is essential and a potential therapeutic target for psoriasis.
Asunto(s)
Proteínas Adaptadoras de Señalización CARD/metabolismo , Guanilato-Quinasas/metabolismo , Células de Langerhans/inmunología , Psoriasis/inmunología , Piel/patología , Linfocitos T/inmunología , Aminoquinolinas/inmunología , Animales , Proteínas Adaptadoras de Señalización CARD/genética , Quimera , Guanilato-Quinasas/genética , Humanos , Imiquimod , Interleucina-17/metabolismo , Interleucina-23/inmunología , Interleucinas/metabolismo , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Modelos Animales , Terapia Molecular Dirigida , Psoriasis/inducido químicamente , Psoriasis/genética , Receptor Toll-Like 7/genética , Receptor Toll-Like 7/metabolismo , Receptor Toll-Like 9/genética , Receptor Toll-Like 9/metabolismo , Transcriptoma , Interleucina-22RESUMEN
BACKGROUND: Resolvin D1 (RvD1), a pro-resolution lipid mediator derived from docosahexaenoic acid (DHA), has been described to promote several kinds of inflammatory resolution. However, the effects and anti-inflammatory mechanisms of RvD1 on psoriasis have not been previously reported. OBJECTIVE: The present study aimed to determine the protective effects and the underlying mechanisms of RvD1 on imiquimod (IMQ)-induced psoriasiform dermatitis. METHODS: Mice were topically treated with IMQ to develop psoriasiform dermatitis on their shaved back, pretreated intraperitoneally (i.p.) with or without RvD1 or tert-butoxycarbonyl Met-Leu-Phe peptide (Boc), a lipoxin A4 (ALX) receptor antagonist. The severity was monitored and graded using a modified human scoring system, the Psoriasis Area and Severity Index (PASI), histopathology, and the signature cytokines of psoriasis (IL-23, IL-17, IL-22 and TNF-α). The mRNA and protein levels of inflammatory cytokines were quantified by quantitative real-time PCR (QRT-PCR) and ELISA. The expressions of signaling proteins MAPKs and NF-κB p65 were analyzed using western blotting. Electrophoretic mobility shift assay (EMSA) was used to check NF-κB p65 DNA binding activity. RESULTS: Our study showed that RvD1 alleviated IMQ-induced psoriasiform dermatitis and improved skin pathological changes. RvD1 markedly inhibited IMQ-induced activation of ERK1/2, p38, JNK (c-Jun N-terminal protein kinase, a subfamily of MAPKs), and NF-κB. Furthermore, pretreatment with Boc, would not exacerbate skin inflammation of IMQ-induced mice, but significantly reversed the beneficial effects of RvD1 on IMQ-induced psoriasiform inflammation. CONCLUSION: RvD1 can obviously improve skin inflammation in IMQ-induced mice psoriasiform dermatitis. The protective mechanisms might be related to its selective reaction with lipoxin A4 receptor/Formyl-peptide receptor 2 (ALX/FPR2), by downregulating relevant cytokines of the IL-23/IL-17 axis expression, the inhibition of MAPKs and NF-κB signaling transduction pathways. Thus, these results show that RvD1 could be a possible candidate for psoriasis therapy.
Asunto(s)
Antiinflamatorios/uso terapéutico , Dermatitis/tratamiento farmacológico , Ácidos Docosahexaenoicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Administración Cutánea , Aminoquinolinas/inmunología , Animales , Antiinflamatorios/farmacología , Dermatitis/inmunología , Dermatitis/patología , Modelos Animales de Enfermedad , Ácidos Docosahexaenoicos/farmacología , Evaluación Preclínica de Medicamentos , Humanos , Imiquimod , Masculino , Ratones , Ratones Endogámicos BALB C , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/metabolismo , Psoriasis/inmunología , Psoriasis/patología , Índice de Severidad de la Enfermedad , Piel/efectos de los fármacos , Piel/metabolismo , Piel/patología , Crema para la Piel/farmacología , Crema para la Piel/uso terapéuticoRESUMEN
BACKGROUND/AIM: Tumor-associated macrophages (TAMs), together with splenic CD11b+ cells, help maintain the tumor microenvironment. The immunomodulatory compound imiquimod (IQM) stimulates innate immune cells, including macrophages, to induce antitumor effects. In order to elucidate the effects of IQM on the tumor microenvironment, we investigated the immunomodulatory effect of IQM during melanoma growth by using the B16F10 melanoma model. MATERIALS AND METHODS: To elucidate the immunomodulatory effects of IQM on the tumor microenvironment, we isolated CD11b+ TAMs and splenic CD11b+ cells and evaluated the immunomodulatory effects of IQM, using the B16F10 melanoma model. RESULTS: IQM suppressed B16F10 melanoma growth in parallel with reduction of Foxp3+ regulatory T cells (Tregs) at the tumor site, caused by the down-regulation of CCL22 production by tumor-derived and splenic CD11b+ cells. Subsequently, we investigated the antitumor or tumor-loading effects of splenic CD11b+ cells on B16F10 melanoma growth in vivo. B16F10 melanoma growth was accelerated by splenic CD11b+ cells from untreated mice, but was inhibited by splenic CD11b+ cells from IQM-treated mice. Consistent with these results, Foxp3+ Tregs were significantly decreased in tumors of mice implanted with both melanoma and splenic CD11b+ cells from topical IQM-treated mice. Furthermore, intratumoral administration of anti-CCL22 antibody inhibited B16F10 melanoma growth by decreasing Treg recruitment at the tumor site. CONCLUSION: Our results suggest a possible mechanism for the antitumor immune response induced by IQM through tumor-associated macrophages.
Asunto(s)
Aminoquinolinas/inmunología , Aminoquinolinas/farmacología , Quimiocina CCL22/metabolismo , Factores Inmunológicos/inmunología , Macrófagos/efectos de los fármacos , Melanoma Experimental/dietoterapia , Melanoma Experimental/metabolismo , Animales , Antígeno CD11b/inmunología , Antígeno CD11b/metabolismo , Línea Celular Tumoral , Quimiocina CCL22/inmunología , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/inmunología , Femenino , Factores de Transcripción Forkhead/inmunología , Factores de Transcripción Forkhead/metabolismo , Imiquimod , Factores Inmunológicos/farmacología , Macrófagos/inmunología , Melanoma Experimental/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/inmunología , Carga Tumoral/efectos de los fármacos , Carga Tumoral/inmunología , Microambiente Tumoral/efectos de los fármacos , Microambiente Tumoral/inmunologíaRESUMEN
Devil facial tumour disease (DFTD) describes two genetically distinct transmissible tumours that pose a significant threat to the survival of the Tasmanian devil. A prophylactic vaccine could protect devils from DFTD transmission. For this vaccine to be effective, potent immune adjuvants will be required. Toll-like receptors (TLRs) promote robust immune responses in human cancer studies and are highly conserved across mammalian species. In this study, we investigated the proficiency of TLR ligands for immune activation in the Tasmanian devil using in vitro mononuclear cell stimulations and in vivo immunisation trials with a model antigen. We identified two such TLR ligands, polyICLC (Hiltonol®) (TLR3) and imiquimod (TLR7), that in combination induced significant IFNγ production from Tasmanian devil lymphocytes in vitro. Immunisation with these ligands and the model antigen keyhole limpet haemocyanin activated robust antigen-specific primary, secondary and long-term memory IgG responses. Our results support the conserved nature of TLR signaling across mammalian species. PolyICLC and imiquimod will be trialed as immune adjuvants in future DFTD vaccine formulations.
Asunto(s)
Aminoquinolinas/inmunología , Antígenos/inmunología , Vacunas contra el Cáncer/inmunología , Carboximetilcelulosa de Sodio/análogos & derivados , Neoplasias Faciales/inmunología , Leucocitos Mononucleares/inmunología , Marsupiales/inmunología , Poli I-C/inmunología , Polilisina/análogos & derivados , Adyuvantes Inmunológicos , Animales , Células Cultivadas , Neoplasias Faciales/prevención & control , Hemocianinas/inmunología , Humanos , Imiquimod , Inmunidad , Inmunidad Innata , Inmunización , Inmunoglobulina G/metabolismo , Activación de Linfocitos , Polilisina/inmunología , Receptores Toll-Like/agonistasRESUMEN
One of the next challenges in cancer immunotherapy is the resistance of tumors to T-cell-based treatments through loss of MHC class I. Here, we show that under these circumstances, the Toll-like receptor (TLR)-7/8 ligand imiquimod, but not the TLR3 ligand poly I:C or TLR9 ligand CpG, mediated an effective antitumor response. The rejection of these immune-escaped cancers was mediated by NK cells and CD4+ T cells, whereas activated CD8+ T cells were dispensable. Application of the innate immune stimulator at a distant site activated NK cells and thereby elicited tumor-specific T-cell responses in tumor-bearing mice. Mechanistically, imiquimod activated NK cells to kill tumor cells, resulting in release of tumor antigens and induction of tumor-specific CD4+ T cells. These T helper cells provoked a strong induction of CXCL9 and CXCL10 in the tumor environment. Simultaneously, imiquimod induced the expression of the cognate chemokine receptor CXCR3 on peripheral lymphocytes. This ignited intratumoral CD4+ T-cell infiltration and accumulation, which was critical for tumor rejection; CXCR3 blocking antibodies mitigated the clinical response. In the effector phase, NK cell recruitment to tumors and their activation depended on CD4+ T cells. Together, we have uncovered a potent immune axis of tumor-specific CD4+ T cells and NK cells that eliminates escaped MHC-Ilow tumors. Cancer Immunol Res; 5(8); 642-53. ©2017 AACR.
Asunto(s)
Células Asesinas Naturales/inmunología , Complejo Mayor de Histocompatibilidad/inmunología , Glicoproteínas de Membrana/inmunología , Neoplasias/inmunología , Receptor Toll-Like 7/inmunología , Microambiente Tumoral/inmunología , Aminoquinolinas/administración & dosificación , Aminoquinolinas/inmunología , Animales , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Quimiocina CXCL10/inmunología , Quimiocina CXCL9/inmunología , Humanos , Imiquimod , Activación de Linfocitos/inmunología , Glicoproteínas de Membrana/agonistas , Ratones , Neoplasias/patología , Neoplasias/terapia , Receptores CXCR3/inmunología , Receptor Toll-Like 3/inmunología , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 9/inmunologíaRESUMEN
BACKGROUND: Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation. Cysteine-rich angiogenic inducer 61 (Cyr61/CCN1) has recently been implicated in psoriasis pathogenesis by promoting keratinocyte activation. However, the mechanisms by which CCN1 enhances cutaneous inflammation are not fully understood. OBJECTIVE: In this study, we investigated the role of CCN1 on the expression of CCL20 in human keratinocyte. METHODS AND RESULTS: By double-label immunofluorescence staining, we first identified that the expression of CCN1 colocalized well with CCL20 production in the epidermis of psoriasis skin lesion. Furthermore, in vivo, blocking or knockdown CCN1 expression ameliorated skin inflammation and reduced the expression of CCL20 in both imiquimod and IL-23-induced psoriasis-like mouse models, which indicated that CCN1 might be involved in the regulation of CCL20 production in psoriasis. Next, in vitro, we stimulated primary normal human epidermal keratinocyte (NHEK) with exogenous protein CCN1 and found that CCN1 directly upregulated CCL20 production independent of TNF-α, IL-22 and IL-17 pathway. Lastly, the signaling pathway study showed that CCN1 enhanced the binding of AP-1 to the CCL20 promoter via crosstalk with p38 and JNK. CONCLUSIONS: Our study demonstrates that CCN1 stimulates CCL20 production in vitro and in vivo, and thus supports the notion that overexpressed CCN1 in hyperproliferating keratinocyte is functionally involved in the recruitment of inflammatory cells to skin lesions affected by psoriasis.
Asunto(s)
Quimiocina CCL20/metabolismo , Proteína 61 Rica en Cisteína/metabolismo , Sistema de Señalización de MAP Quinasas , Psoriasis/patología , Aminoquinolinas/inmunología , Animales , Biopsia , Proteína 61 Rica en Cisteína/genética , Modelos Animales de Enfermedad , Epidermis/inmunología , Epidermis/patología , Femenino , Técnicas de Silenciamiento del Gen , Humanos , Imiquimod , Interleucina-23/inmunología , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Queratinocitos , Activación de Linfocitos , Ratones , Ratones Endogámicos BALB C , Cultivo Primario de Células , Regiones Promotoras Genéticas , Psoriasis/inmunología , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Factor de Transcripción AP-1/metabolismo , Factor de Necrosis Tumoral alfa , Regulación hacia Arriba , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismoRESUMEN
BACKGROUND: Psoriasis patients are at increased risk of developing lipid metabolism disturbances. Both psoriasis and dyslipideamia not only closely interact in disease development, but occur as mutual side effects in some medicine treatment. The interactive mechanism of the two diseases is complicated and still unclear. OBJECTIVE: Here, we proposed applying imiquimod on the dorsal skin of ApoE-/- mice to establish a composite animal model which formed psoriasiform skin lesions under hyperlipidemic condition. METHOD: By comparison with corresponding wild-type(C57BL/6) mice, the composite mice model was evaluated by skin pathological features, lipid levels, immune inflammatory factors in order to clarify the diseases interplay mechanism. In addition, IL-17 mAb treatment was applied to observe the effect of IL-17 antibody on the composite animal model. RESULTS: The results verified that imiquimod-induced ApoE-/- mice model presented keratinocyte hyperplasia, parakeratosis, inflammatory cells infiltration and elevated serum lipid levels, and also reflected the complex interaction between inflammation and lipid metabolism. IL-17 mAb could inhibit psoriasis skin lesions with lipid accumulation via STAT3 pathway, but no influence on elevated serum cholesterol. CONCLUSIONS: Imiquimod-induced ApoE-/- mice model presented the pathological features of psoriasis and dyslipideamia, which could be an ideal composite animal model for the study of pathogenesis and pharmacotherapeutics of psoriasis and dyslipideamia comorbidity.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Aminoquinolinas/inmunología , Modelos Animales de Enfermedad , Dislipidemias/epidemiología , Psoriasis/epidemiología , Piel/inmunología , Administración Cutánea , Aminoquinolinas/farmacología , Animales , Dorso , Proliferación Celular , Colesterol/sangre , Comorbilidad , Dislipidemias/sangre , Dislipidemias/inmunología , Imiquimod , Interleucina-17/antagonistas & inhibidores , Queratinocitos/inmunología , Queratinocitos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados para ApoE , Psoriasis/sangre , Psoriasis/inmunología , Factor de Transcripción STAT3/metabolismo , Transducción de Señal , Piel/citología , Piel/patologíaRESUMEN
The thymus contains a low frequency of B cells, about 0.1-0.5% of total population of thymocytes that were shown to contribute in thymic negative selection. The fact that B cells in the periphery have been contributed in the generation of the T regulatory cell compartment emerged the idea that this process may indeed be initiated firstly within the thymus. The results of this study revealed that activated thymic B cells maintained the high percentage of nTreg generation or counteracted the decrease of this percentage observed in non-activated culture, and both activators (LPS and IMQ) have the same effect in the process of nTreg generation by B cells. In addition, the activated cultures showed increase of the level of expression of Foxp3 transcription factor. In this study we confirmed that thymic B cells in the condition of our experiments did not influence the generation of nTregs, but rather maintain their viability when activated by both activators.
Asunto(s)
Linfocitos B/inmunología , Subgrupos de Linfocitos T/inmunología , Linfocitos T Reguladores/inmunología , Timocitos/inmunología , Timo/inmunología , Aminoquinolinas/inmunología , Animales , Antígenos CD/metabolismo , Diferenciación Celular , Células Cultivadas , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Antígenos de Histocompatibilidad Clase II/metabolismo , Imiquimod , Lipopolisacáridos/inmunología , Activación de Linfocitos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones NoqueadosRESUMEN
The disorder of B cells is one of the hallmarks of systemic lupus erythematosus (SLE). The activation state indicated by CD86 of B cells from SLE is well known, while the defect of regulatory B cells mediated by CD1d is also responsible for the process of SLE. In the present study, we focused on the relationship between B cell activation mediated by CD86 and B cell regulatory function mediated by CD1d. Our results showed that the level of CD1d in B cells was decreased during the early stages of B6.MRLlpr SLE mice and imiquimod-treated (IMQ-treated) mice, while the level of CD86 was significantly increased at the late stage. Moreover, the expression of CD1d showed a significantly negative correlation with CD86 level in B cells from IMQ-treated mice (r = -05741; P = 0.0022), B6.MRLlpr mice (r = -0.7091; P = 0.0268), and SLE patients (r = -0.4125; P = 0.0404). The in vivo and in vitro experiments with splenocytes demonstrated that CD1d signaling pathway could inhibit toll-like receptor 7 (TLR7)-induced CD86 expression of B cells. Further studies showed that this relationship also affected antibody production. Thus, our results confirmed the association of CD1d and CD86 levels in B cells from SLE, and demonstrated the importance to preserve the immunoregulatory function of B cells mediated by CD1d in the progression of SLE.
Asunto(s)
Antígenos CD1d/inmunología , Linfocitos B/inmunología , Antígeno B7-2/inmunología , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Aminoquinolinas/inmunología , Animales , Antígenos CD1d/genética , Antígenos CD1d/metabolismo , Linfocitos B/metabolismo , Antígeno B7-2/genética , Antígeno B7-2/metabolismo , Western Blotting , Femenino , Citometría de Flujo , Humanos , Imiquimod , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/metabolismo , Activación de Linfocitos/inmunología , Ratones Endogámicos C57BL , Ratones Endogámicos MRL lpr , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/inmunología , Bazo/citología , Bazo/inmunología , Bazo/metabolismo , Receptor Toll-Like 7/inmunología , Receptor Toll-Like 7/metabolismo , Adulto JovenRESUMEN
A novel powder-form combination adjuvant system containing two immunostimulatory compounds was firstly developed and evaluated as a therapeutic intervention for cancer immunotherapy. With the help of hyaluronic acid (HA), water insoluble monophosphoryl lipid A (MPL), QS21 and imiquimod (R837), could be easily dispersed in aqueous solution and lyophilized as powder-form, which have an advantage in room-temperature storage stability compared with those conventional liquid formulation that requires cold storage. Two kinds of HA-based combination vaccine adjuvants (HA/MPL/QS21, HMQ and HA/MPL/R837, HMR) contributed to the increase of both humoral and cellular immunity, which is very important for efficient cancer immunotherapy. Through the challenge experiments in EG7-OVA (mouse lymphoma-expressing OVA) tumor-bearing mice model, we found out that the immunostimulatory effects of HMQ and HMR were successful in the inhibition of tumor proliferation. Taken together, both HA-based powder-form combination adjuvant systems are expected to be used as potent prophylactic and therapeutic cancer vaccine.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Ácido Hialurónico/farmacología , Linfoma/terapia , Adyuvantes Inmunológicos/química , Aminoquinolinas/química , Aminoquinolinas/inmunología , Aminoquinolinas/uso terapéutico , Animales , Vacunas contra el Cáncer/química , Vacunas contra el Cáncer/inmunología , Portadores de Fármacos , Femenino , Ácido Hialurónico/química , Enlace de Hidrógeno , Imiquimod , Inmunoterapia , Lípido A/análogos & derivados , Lípido A/química , Lípido A/inmunología , Lípido A/uso terapéutico , Linfoma/inmunología , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Saponinas/química , Saponinas/inmunología , Saponinas/uso terapéutico , SolubilidadRESUMEN
Patients with inflammatory autoimmune diseases are routinely treated with synthetic glucocorticoids to suppress immunopathology. A crucial outcome of glucocorticoid exposure is induction of glucocorticoid-induced leucine zipper (GILZ), a protein with multiple functions that include inhibition of key immune cell signalling pathways. Here we report that GILZ maintains a threshold for activation of Th17 responses and IL-17-dependent pathology. GILZ expression was deficient in lesional skin of psoriasis patients and was negatively correlated with the pro-inflammatory cytokines IL-23, IL-17A and IL-22, and with STAT3 expression. Deficiency of GILZ in mice resulted in excessive inflammation and pro-inflammatory cytokine expression in the imiquimod model of psoriasis, and dendritic cells lacking GILZ produced greater IL-1, IL-23 and IL-6 in response to imiquimod stimulation in vitro. These cytokines stimulate Th17 cell differentiation, and we found unchallenged GILZ-deficient mice to have spontaneous production of IL-17A and IL-22 in vivo. We also identified a T cell-intrinsic role for GILZ in limiting Th17 cell formation in vitro in response to Th17-promoting cytokines IL-1ß and IL-23. Addition of IL-6 under these conditions suppressed GILZ, allowing T cell proliferation and expression of Th17 genes, whereas exogenous delivery of GILZ using a cell-permeable fusion protein restored regulation of Th17 cell proliferation. Thus, GILZ has a non-redundant function to constrain pathogenic Th17 responses, with clinical implications for psoriasis.
Asunto(s)
Dermatitis/inmunología , Interleucina-17/inmunología , Células Th17/inmunología , Factores de Transcripción/inmunología , Aminoquinolinas/inmunología , Aminoquinolinas/farmacología , Animales , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Diferenciación Celular/inmunología , Proliferación Celular/efectos de los fármacos , Proliferación Celular/genética , Células Cultivadas , Citocinas/genética , Citocinas/inmunología , Citocinas/metabolismo , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Dermatitis/genética , Dermatitis/metabolismo , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Expresión Génica/efectos de los fármacos , Expresión Génica/inmunología , Humanos , Imiquimod , Interleucina-17/genética , Interleucina-17/metabolismo , Interleucina-6/inmunología , Interleucina-6/farmacología , Lipopolisacáridos/inmunología , Lipopolisacáridos/farmacología , Ratones Endogámicos C57BL , Ratones Noqueados , Psoriasis/genética , Psoriasis/inmunología , Psoriasis/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Th17/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
PURPOSE: Adjuvants are required to ensure the efficacy of subunit vaccines. Incorporating molecular immunopotentiators within particles could overcome drawbacks of molecular adjuvants (such as solubility and toxicity), and improve adjuvanticity of particles, achieving stronger adjuvant activity. Aim of this study is to evaluate the adjuvanticity of immunopotentiator-loaded polymeric particles for subunit vaccine. METHODS: PLGA microparticles (PMPs) and imiquimod (TLR-7 ligand)-loaded PLGA microparticles (IPMPs) were prepared by SPG premix membrane emulsification. In vitro and in vivo studies were performed to their adjuvant activity, using ovalbumin and H5N1 influenza split vaccine as antigens. RESULTS: Incorporating imiquimod into microparticles significantly improved the efficacy of PLGA microparticles in activating BMDCs and pMΦs, and antigen uptake by pMΦs was also promoted. IPMPs showed stronger adjuvanticity to augment OVA-specific immune responses than PMPs. IgG subclass profiles and cytokine secretion levels by splenocytes indicated that IPMPs elicited more Th1-polarized immune response, compared to PMPs. In vivo study using H5N1 influenza split vaccine as antigen also confirmed the effects of IPMPs on antigen-specific cellular immunity. CONCLUSIONS: Considering adjuvanticity and safety profiles (PLGA and IMQ, both approved by FDA), we conclude that IMQ-loaded PLGA microparticles are promising robust adjuvant for subunit vaccines.
Asunto(s)
Adyuvantes Inmunológicos/química , Adyuvantes Inmunológicos/farmacología , Polímeros/química , Vacunas/inmunología , Adyuvantes Farmacéuticos/química , Adyuvantes Farmacéuticos/farmacología , Aminoquinolinas/química , Aminoquinolinas/inmunología , Animales , Antígenos/inmunología , Femenino , Imiquimod , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/inmunología , Inmunoglobulina G/inmunología , Subtipo H5N1 del Virus de la Influenza A/efectos de los fármacos , Subtipo H5N1 del Virus de la Influenza A/inmunología , Ácido Láctico/química , Masculino , Ratones , Ratones Endogámicos C57BL , Ovalbúmina/inmunología , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Vacunas/químicaRESUMEN
PURPOSE: Activation of immune cells through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) or NOD-like receptors (NLRs), has been identified as a key issue in the development of new efficient vaccine adjuvants. We report here on the elaboration and immunostimulatory potential of polylactide (PLA)-based micelles core-loaded with imiquimod TLR7 ligand and able to be further surface-functionalized with antigenic protein (HIV-1 Gag p24) for antigen delivery purpose. METHODS: Micelles prepared from poly(D,L-lactide)-b-poly(N-acryloxysuccinimide-co-N-vinylpyrrolidone) amphiphilic copolymer were incubated in the presence of imiquimod, leading to 1.2 wt% loading, and further conjugated to p24 antigen through reaction of p24 lysines and N-terminal amine with the N-succinimidyl pendant groups of the micelle corona. The impact of imiquimod encapsulation in the micelles on its immunostimulatory properties was investigated in vitro, by monitoring: (i) the NF-κB and mitogen-activated protein kinases (MAPK) pathways through experiments with RAW-Blue™ cells, a mouse macrophage cell line encoding an NF-κB/AP-1-inducible reporter construct; (ii) human dendritic cells (DCs) maturation markers by flow cytometry. RESULTS: RAW-Blue™ cells based experiments showed that imiquimod encapsulated in the micelles was much more efficient to activate the NF-κB and MAPK pathways than free imiquimod. Furthermore, encapsulated imiquimod was found to induce much higher maturation of DCs than the free analog. Finally, these immunostimulatory properties of the loaded imiquimod were shown to be conserved when the p24 antigen was coupled at the micelle surface. CONCLUSIONS: Taken together, these data regarding improved immunostimulatory efficiency suggest the strong potential of our micelle-based nano-system for vaccine delivery.